Insider Trading April 1, 2026

CoreWeave Development Chief Disposes $9.9M in CRWV Shares; Simultaneous Class B Conversions Executed

Brannin McBee’s March 30 transactions include multiple block sales under a 10b5-1 plan and parallel conversions of Class B stock into Class A shares

By Jordan Park CRWV
CoreWeave Development Chief Disposes $9.9M in CRWV Shares; Simultaneous Class B Conversions Executed
CRWV

CoreWeave Chief Development Officer Brannin McBee executed roughly $9.9 million in sales of Class A Common Stock on March 30, 2026, across several blocks and at prices between $67.67 and $75.19 per share. The sales - made directly, via an irrevocable trust, and through shares held by a spouse - were conducted under a pre-arranged Rule 10b5-1 plan adopted on November 17, 2025. On the same day McBee and related parties also converted Class B Common Stock into Class A shares. The insider activity coincides with company-level financing developments, including an $8.5 billion delayed draw term loan facility and recent benchmark performance results in the MLPerf Inference v6.0 suite.

Key Points

  • Brannin McBee sold approximately $9.9 million of CoreWeave Class A Common Stock on March 30, 2026, through direct sales, a 2022 irrevocable trust, and shares held by a spouse.
  • The sales took place at prices ranging from $67.67 to $75.19 per share - below the then-current market price of $78.44 - and were carried out under a Rule 10b5-1 trading plan adopted on November 17, 2025.
  • On the same day, McBee and related parties converted Class B Common Stock into Class A shares (100,000 shares for McBee; 27,085 for the trust; 16,665 for spouse), and the company announced an $8.5 billion delayed draw term loan facility and reported MLPerf Inference v6.0 benchmark gains.

Brannin McBee, CoreWeave Inc.'s Chief Development Officer, sold a combined total of Class A Common Stock valued at approximately $9.9 million on March 30, 2026, according to a Form 4 filing with the Securities and Exchange Commission.

The transactions took place at per-share prices ranging from $67.67 to $75.19, prices that were below the then-current market quote of $78.44. The filing situates the sales amid a recent decline in the company's share price - a drop of 11.54% over the prior week, as reported by InvestingPro data.


Breakdown of direct sales by Brannin McBee

  • 33,090 shares at a weighted average of $67.6666
  • 20,603 shares at a weighted average of $68.7648
  • 23,907 shares at a weighted average of $69.6511
  • 12,600 shares at a weighted average of $70.5452
  • 4,800 shares at a weighted average of $71.6821
  • 2,200 shares at a weighted average of $72.6445
  • 1,300 shares at a weighted average of $74.1185
  • 1,500 shares at a weighted average of $74.8667

Sales by the Brannin J. McBee 2022 Irrevocable Trust

  • 8,979 shares at a weighted average of $67.6697
  • 5,688 shares at a weighted average of $68.766
  • 6,405 shares at a weighted average of $69.6672
  • 3,372 shares at a weighted average of $70.5605
  • 1,300 shares at a weighted average of $71.6648
  • 609 shares at a weighted average of $72.6718
  • 529 shares at a weighted average of $74.3451
  • 203 shares at a weighted average of $75.1909

Sales by Spouse

  • 5,525 shares at a weighted average of $67.6696
  • 3,499 shares at a weighted average of $68.766
  • 3,941 shares at a weighted average of $69.6672
  • 2,075 shares at a weighted average of $70.5604
  • 800 shares at a weighted average of $71.6647
  • 375 shares at a weighted average of $72.672
  • 325 shares at a weighted average of $74.3454
  • 125 shares at a weighted average of $75.19

The Form 4 filing notes that these dispositions were carried out pursuant to a pre-established Rule 10b5-1 trading plan that McBee adopted on November 17, 2025. The filing does not provide additional commentary beyond the mechanics of the trades and the existence of the plan.


Concurrent conversions into Class A shares

On the same date, McBee and related parties completed conversions of Class B Common Stock into Class A Common Stock. The filing records the following conversions:

  • 100,000 Class A shares acquired by McBee through conversion
  • 27,085 Class A shares acquired for the Brannin J. McBee 2022 Irrevocable Trust through conversion
  • 16,665 Class A shares acquired by Spouse through conversion

The Form 4 does not indicate any further transactions tied to the converted shares beyond their issuance through conversion on March 30, 2026.


Company-level context included in the filing and related disclosures

The insider activity arrives while CoreWeave is undertaking substantial financing initiatives and reporting performance benchmarks for its high-performance computing offerings. The company closed an $8.5 billion delayed draw term loan facility intended to support expansion of its AI cloud platform. Credit agencies assigned investment-grade assessments to that financing - A3 from Moody's and A (low) from DBRS - a designation the filing highlights as notable for financing backed by high-performance computing infrastructure and associated customer contracts.

The new facility was described as oversubscribed, with participation from global financing institutions, asset managers, and insurance investors. Market research and broker reactions included Evercore ISI reiterating an Outperform rating with a $120.00 price target, Stifel maintaining a Hold rating with a $110.00 price target, and Citizens reiterating a Market Outperform rating with a $180.00 price target - commentary that accompanied the financing announcement in disclosures cited in the filing.

Separately, the company reported benchmark performance in the MLPerf Inference v6.0 suite, where CoreWeave's Nvidia GB200 and GB300 systems demonstrated meaningful performance improvements in the reported results.


Financial pointers cited in supplemental material

Supplementary highlights referenced in the filing note that CoreWeave's levered free cash flow was negative $7.25 billion over the last twelve months, a figure identified in InvestingPro Tips that accompanied the transaction filing. The filing also points users to additional InvestingPro research offerings and proprietary tips for deeper analysis, though the Form 4 itself contains only the transaction-level disclosures and the mechanics described above.

This article presents the transaction detail as reported in the SEC filing and the company-level disclosures cited alongside it. The filing contains the sales, the conversions, and the statement that the sales were executed under the Rule 10b5-1 plan adopted on November 17, 2025; the document does not offer further explanation of motivation or future plans.

Risks

  • CoreWeave's levered free cash flow was negative $7.25 billion over the last twelve months, a financial metric noted alongside the filing - an uncertainty for capital-intensive operations and markets tied to high-performance computing.
  • The company's stock had declined 11.54% over the week leading to the transactions, indicating recent market volatility that may affect equity valuations in the cloud infrastructure and AI compute sectors.
  • The Form 4 and related disclosures provide transaction mechanics but do not include management commentary on motives or intended use of proceeds, leaving interpretation of insider activity limited to the facts disclosed.

More from Insider Trading

Gevo COO Sells 129,797 Shares as Company Posts Strong Revenue Gain but Remains Unprofitable Apr 1, 2026 Dianthus Therapeutics Director Disposes of $47,985 in Shares, Exercises Options Apr 1, 2026 Dianthus CFO Sells $9.5M in Stock as Company Completes $719M Offering Apr 1, 2026 Processa Pharmaceuticals R&D President Buys 1,810 PCSA Shares; Company Reports Phase 2 Dosing Complete Apr 1, 2026 Processa Pharmaceuticals director buys $5,252 of PCSA stock, increases direct holding Apr 1, 2026